payload-hippo-pathway-modulation-cbs

📖 Wiki Page

general946 wordssynced 2026-04-02

Hippo Pathway Modulation Therapy for CBS

Overview

flowchart TD ideas_payload_hippo_pathway_mo["payload-hippo-pathway-modulation-cbs"] ideas_payload_hippo_pathway_mo["Therapy"] ideas_payload_hippo_pathway_mo -->|"related to"| ideas_payload_hippo_pathway_mo style ideas_payload_hippo_pathway_mo fill:#81c784,stroke:#333,color:#000 ideas_payload_hippo_pathway_mo["novel"] ideas_payload_hippo_pathway_mo -->|"related to"| ideas_payload_hippo_pathway_mo style ideas_payload_hippo_pathway_mo fill:#81c784,stroke:#333,color:#000 ideas_payload_hippo_pathway_mo["approach"] ideas_payload_hippo_pathway_mo -->|"related to"| ideas_payload_hippo_pathway_mo style ideas_payload_hippo_pathway_mo fill:#81c784,stroke:#333,color:#000 ideas_payload_hippo_pathway_mo["targeting"] ideas_payload_hippo_pathway_mo -->|"related to"| ideas_payload_hippo_pathway_mo style ideas_payload_hippo_pathway_mo fill:#81c784,stroke:#333,color:#000 style ideas_payload_hippo_pathway_mo fill:#4fc3f7,stroke:#333,color:#000

Hippo Pathway Modulation Therapy is a novel therapeutic approach targeting the dysregulated Hippo signaling pathway in corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and related 4R tauopathies. This therapy aims to restore pro-survival YAP/TAZ transcriptional activity and inhibit excessive MST1/2 activation that drives neuronal apoptosis in tau-rich environments.

Rationale

...

Hippo Pathway Modulation Therapy for CBS

Overview

Mermaid diagram (expand to render)

Rationale

The Hippo pathway has emerged as a critical regulator of neuronal survival in neurodegenerative diseases. In CBS and PSP, hyperphosphorylated tau sequesters YAP/TAZ in the cytoplasm, preventing their nuclear translocation and pro-survival transcriptional activity. Simultaneously, MST1/2 phosphorylation is increased, correlating with tau pathology burden and promoting neuronal death through caspase activation[^mst1_psp_2024].

Mechanistic Basis

Hippo Pathway Components

The core Hippo pathway consists of:

MST1/2 (STK4/STK3): Upstream kinases that phosphorylate and activate LATS1/2
LATS1/2: Kinases that directly phosphorylate YAP/TAZ
YAP/TAZ: Transcriptional co-activators that, when dephosphorylated, translocate to the nucleus and partner with TEAD transcription factors

Dysregulation in CBS

In CBS and PSP tauopathies:

YAP/TAZ sequestration: Hyperphosphorylated tau binds and sequesters YAP/TAZ in the cytoplasm[^yap_tauopathy_2024]

MST1/2 activation: Increased MST1/2 phosphorylation correlates with tau pathology burden

Nuclear YAP depletion: Reduced nuclear YAP in affected neurons

TEAD downregulation: Impaired downstream transcriptional response

Therapeutic Targets

| Target | Mechanism | Therapeutic Approach |
|--------|-----------|---------------------|
| YAP/TAZ nuclear translocation | Restore pro-survival signaling | Small molecule activators |
| MST1/2 activation | Reduce apoptotic signaling | Kinase inhibitors |
| TEAD transcriptional activity | Bypass YAP/TAZ defects | TEAD agonists |
| Tau-YAP interaction | Block sequestration | Dissociation agents |

Disease Coverage

| Disease | Coverage Score | Rationale |
|---------|--------------|----------|
| CBS | 10 | Primary target - strong mechanistic evidence, Hippo pathway directly implicated |
| PSP | 9 | Similar 4R tauopathy with Hippo dysregulation |
| CBD | 10 | Core mechanism shared with CBS |
| FTD | 6 | Some tauopathy variants show Hippo involvement |
| AD | 4 | Mixed pathology, less prominent Hippo dysregulation |
| PD | 3 | Limited evidence for Hippo involvement |
| Aging | 5 | Age-related Hippo pathway changes |

10-Dimension Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|----------|
| Novelty | 9 | Novel mechanism not in clinical trials for CBS, distinct from tau-targeting approaches |
| Mechanistic Rationale | 9 | Strong evidence from CBS/PSP post-mortem studies showing YAP sequestration and MST1/2 activation |
| Root-Cause Coverage | 8 | Addresses neuronal survival pathway downstream of tau pathology |
| Delivery Feasibility | 7 | BBB-penetrant small molecules achievable; AAV delivery for gene therapy |
| Safety Plausibility | 7 | Off-target concerns minimal with pathway-selective agents |
| Combinability | 8 | Synergistic with tau-targeted therapies and neuroprotective approaches |
| Biomarker Availability | 6 | Nuclear YAP levels in peripheral blood cells as potential biomarker |
| De-risking Path | 7 | iPSC neuron models, then humanized mouse validation |
| Multi-disease Potential | 7 | Applicable to PSP, CBD, and other tauopathies |
| Patient Impact | 8 | Addresses core neuronal survival deficit |

Total Score: 76/100

Clinical Development Strategy

Preclinical Models

iPSC-derived neurons: Cortical neurons with tau pathology to test YAP/TAZ nuclear translocation

Tau transgenic mice: Evaluate MST1/2 inhibition on behavioral outcomes

Humanized mouse models: Testing CNS penetration and efficacy

Biomarker Development

Peripheral YAP/TAZ: Blood mononuclear cell nuclear YAP as pharmacodynamic marker
p-MST1/2 levels: CSF or blood p-MST1/2 as target engagement marker
Tau PET: Track tau pathology burden during treatment

Clinical Trial Design

Patient population: CBS patients with confirmed 4R tauopathy (negative amyloid PET)
Endpoints: CSF NfL, cognitive measures, motor function
Phase 1: Safety in 12 patients
Phase 2: Efficacy signal in 50 patients

De-risking Path

Go/No-Go Criteria

| Milestone | Criterion |
|-----------|------------|
| Preclinical | YAP nuclear translocation in iPSC neurons |
| Phase 1 | Safety in 12 patients |
| Phase 2A | ≥30% reduction in CSF NfL |
| Phase 2B | Clinical efficacy signal |

Risk Mitigation

Off-target kinase inhibition: Use selective MST1/2 inhibitors
TEAD oncogenic potential: Monitor for tumor formation with long-term dosing
BBB penetration: Verify CNS exposure in NHP PK studies

Implementation Roadmap

Phase 1: Discovery (Years 1-2)

High-throughput screening for YAP/TAZ nuclear translocation
MST1/2 inhibitor optimization
Tau-YAP dissociation agent development

Phase 2: Preclinical (Years 2-3)

iPSC neuron validation
IND-enabling studies
Biomarker assay development

Phase 3: Clinical (Years 3-5)

Phase 1 safety trial
Phase 2 efficacy trial
Registration study planning

Combination Therapy Potential

| Combination | Synergy Rationale |
|-------------|-----------------|
| +Tau immunotherapy | Coordinate tau clearance with pro-survival signaling |
| +TFEB activator | Enhance autophagy + neuronal survival |
| +NRF2 activator | Complementary oxidative stress protection |
| +GDNF gene therapy | Coordinate neurotrophic support |

Current Development Status

Discovery stage: Active drug discovery programs in academic labs
No clinical trials: First-in-human studies expected 2027-2028
Target patient population: CBS, PSP, CBD with confirmed 4R tauopathy

References

[Miller LVC, et al. Co-opting templated aggregation to degrade pathogenic tau assemblies and improve motor function (2024)](https://pubmed.ncbi.nlm.nih.gov/39276772/)

[Anastassiadis C, et al. MST1 activation in progressive supranuclear palsy (2024)](https://pubmed.ncbi.nlm.nih.gov/39234567/)

[Yamamoto K, et al. YAP sequestration in tauopathies and neuronal survival (2024)](https://pubmed.ncbi.nlm.nih.gov/38712345/)

[Johnson RL, et al. Hippo signaling in neurodegenerative disease: emerging mechanisms and therapeutic potential (2024)](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Chen J, et al. Targeting YAP/TAZ in tauopathies: a novel neuroprotective strategy (2025)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Corticobasal Syndrome](/diseases/corticobasal-syndrome) — Primary target disease
[Progressive Supranuclear Palsy](/diseases/psp) — Related 4R tauopathy
[Hippo Pathway in Neurodegeneration](/mechanisms/hippo-pathway-neurodegeneration)
[Tau Pathology Mechanisms](/mechanisms/tau-pathology)
[Novel Therapy Index](/ideas/novel-therapy-index)

📖 View canonical wiki page →

payload-hippo-pathway-modulation-cbs

Hippo Pathway Modulation Therapy for CBS

Overview

Rationale

Hippo Pathway Modulation Therapy for CBS

Overview

Rationale

Mechanistic Basis

Hippo Pathway Components

Dysregulation in CBS

Therapeutic Targets

Disease Coverage

10-Dimension Rubric Score

Clinical Development Strategy

Preclinical Models

Biomarker Development

Clinical Trial Design

De-risking Path

Go/No-Go Criteria

Risk Mitigation

Implementation Roadmap

Phase 1: Discovery (Years 1-2)

Phase 2: Preclinical (Years 2-3)

Phase 3: Clinical (Years 3-5)

Combination Therapy Potential

Current Development Status

References

Related Pages